查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571414

十二指腸潰瘍治療市場規模、佔有率、趨勢分析報告：依治療方法、給藥途徑、通路、地區和細分市場預測，2024-2030年

Duodenal Ulcer Treatment Market Size, Share & Trends Analysis Report By Treatment, By Route Of Administration, By Distribution Channel, By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 90 Pages | 商品交期: 2-10個工作天內

價格

十二指腸潰瘍治療市場的成長與趨勢：

Grand View Research最新報告顯示，預計2024年至2030年全球十二指腸潰瘍治療市場規模將以3.18%的複合年成長率成長，2030年將達到55.4億美元。

該市場包括專注於十二指腸潰瘍（十二指腸內壁形成的潰瘍）管理和治療的各種組成部分。

藥物治療對於十二指腸潰瘍治療市場至關重要。這些藥物包括質子幫浦阻斷劑(PPI)、組織胺受體拮抗劑 (H2RA)、針對幽門螺旋桿菌感染的抗生素、黏膜保護劑和制酸劑。這些藥物減少胃酸分泌，殺死細菌病原體，增強黏膜防禦，中和胃酸。這種治療方法可以促進潰瘍癒合，同時緩解腹脹、腹痛和不適。

由於行動應用程式、遠端醫療平台和遠端監控工具等數位健康解決方案的引入，該市場正在經歷顯著成長。這些技術可實現個人化治療管理、即時症狀追蹤並增強病人參與。此外，還採用人工智慧（AI）演算法來分析大型資料集，以促進改善治療結果和早期發現潰瘍問題。

十二指腸潰瘍治療市場報告亮點

  • 從治療方法方式來看，質子幫浦阻斷劑（PPI）因其在管理和治療十二指腸潰瘍方面的卓越功效而佔據市場主導地位，2023年其銷售佔有率最大，為52.3%。 PPI 的廣泛使用得益於其良好的安全性和高耐受性。 PPI 的廣泛使用得益於其良好的安全性和高耐受性。 PPI 有多種製劑可供選擇，包括可提高病患依從性和便利性的緩釋性製劑。
  • 從給藥途徑來看，口服製劑佔市場主導地位，2023年銷售額佔有率最大，為78.44%。口服製劑通常比注射劑或靜脈注射製劑更具成本效益，這有助於其廣泛使用。其廣泛的市場影響和經過驗證的功效增強了其在治療市場中領先的收益佔有率。
  • 從通路來看，零售藥房細分市場佔據主導地位，2023年銷售佔有率最大，為57.45%。零售藥局讓患者可以立即獲得藥物，而無需去看醫院或專科醫生，從而提高了便利性和用藥依從性。此外，已建立的分銷網路和客戶服務促進了高效的藥物管理和補充流程，進一步增加了該管道的收益。
  • 按地區分類，北美地區佔據市場主導地位，2023 年佔 39.54% 的主要佔有率。這是由持續創新和廣泛的醫療基礎設施所推動的。創新包括開發新的藥物配方和藥物傳輸系統，旨在提高患者的依從性和治療效果。

目錄

第1章調查方法和範圍

第 2 章執行摘要

第3章十二指腸潰瘍治療市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場推動要素分析
    • 市場限制因素分析
  • 十二指腸潰瘍治療市場分析工具
    • 產業分析-波特五力分析
    • PESTEL分析

第4章十二指腸潰瘍治療市場：治療方法預估及趨勢分析

  • 全球十二指腸潰瘍治療市場：治療方法儀表板
  • 全球十二指腸潰瘍治療市場：治療方法變異分析
  • 按治療方法的收益
  • 質子幫浦抑制劑
  • H2拮抗劑
  • 抗生素
  • 其他

第5章十二指腸潰瘍治療市場：給藥途徑預估及趨勢分析

  • 全球十二指腸潰瘍治療市場：途徑儀表板
  • 全球十二指腸潰瘍治療市場：給藥途徑變化分析
  • 按途徑的收益
  • 口服
  • 胃腸外的

第6章十二指腸潰瘍治療市場：通路估算及趨勢分析

  • 全球十二指腸潰瘍治療市場：通路儀表板
  • 全球十二指腸潰瘍治療市場：通路波動分析
  • 按通路分類的收益
  • 零售藥房
  • 醫院藥房
  • 其他

第7章十二指腸潰瘍治療市場：按地區的治療、給藥途徑、通路、估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析：
  • 北美洲
  • 歐洲
  • 亞太地區
  • 拉丁美洲
  • 中東/非洲

第8章 競爭格局

  • 公司/競爭對手分類
  • 供應商情況
    • 主要經銷商及通路夥伴名單
    • Key company market share analysis, 2023
    • GSK plc.
    • Pfizer
    • Abbott
    • Merck KGaA
    • NIHON GENERIC Co., Ltd.
    • Novartis AG
    • Bristol-Myers Squibb Company
    • AstraZeneca
    • Takeda Pharmaceutical Company Limited
    • Eisai Co., Ltd.
Product Code: GVR-4-68040-446-2

Duodenal Ulcer Treatment Market Growth & Trends:

The global duodenal ulcer treatment market size is anticipated to reach USD 5.54 billion by 2030, growing at a CAGR of 3.18% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market encompasses a range of elements focused on the management and treatment of duodenal ulcers, which are sores that occur in the lining of the duodenum.

Pharmacological treatments are crucial to the duodenal ulcer treatment market. These medications include proton pump inhibitors (PPIs), histamine receptor antagonists (H2RAs), and antibiotics targeting Helicobacter pylori infections, mucosal protectants, and antacids. These medications reduce gastric acid production, eradicate bacterial pathogens, enhance mucosal defense, or neutralize stomach acid. This therapeutic approach alleviates bloating, abdominal pain, and discomfort while accelerating ulcer healing.

The market is experiencing significant growth due to the incorporation of digital health solutions such as mobile apps, telemedicine platforms, and remote monitoring tools. These technologies enable personalized treatment management, real-time symptom tracking, and enhanced patient engagement. Additionally, artificial intelligence (AI) algorithms are being employed to analyze large datasets, which improves treatment outcomes and facilitates early detection of ulcer issues.

Duodenal Ulcer Treatment Market Report Highlights:

  • Based on treatment, the proton pump inhibitors dominated the market with the largest revenue share of 52.3% in 2023 due to their superior effectiveness in managing and healing duodenal ulcers.The widespread use of PPIs is driven by their favorable safety profile and high tolerability. They are available in various formulations, including extended-release options, which enhance patient compliance and convenience.
  • Based on route of administration, the oral segment dominated the market with the largest revenue share of 78.44% in 2023. Oral formulations are generally more cost-effective than injectable or intravenous options, contributing to their widespread use. Their extensive market presence and proven efficacy reinforce their leading revenue share in the treatment market.
  • Based on distribution channel, the retail pharmacies segment dominated the market with the largest revenue share of 57.45% in 2023. Retail pharmacies offer patients immediate access to medications without needing hospital or specialist visits, enhancing convenience and adherence. Their established distribution networks and customer service also facilitate efficient medication management and refill processes, further driving revenue in this channel.
  • Based on region, the North America region dominated the market with a significant share of 39.54% in 2023. This is driven by continuous innovation and extensive healthcare infrastructure. Innovations include the development of novel drug formulations and delivery systems aimed at improving patient compliance and treatment efficacy.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Treatment
    • 1.2.2. Route of Administration
    • 1.2.3. Distribution Channel
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Treatment Outlook
    • 2.2.2. Route of Administration Outlook
    • 2.2.3. Distribution Channel Outlook
    • 2.2.4. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Duodenal Ulcer Treatment Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of duodenal ulcers
      • 3.2.1.2. Advancements in treatment options
      • 3.2.1.3. Growing awareness and education about gastrointestinal health
      • 3.2.1.4. Growing geriatric population
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High treatment costs
      • 3.2.2.2. Low reimbursement policies
  • 3.3. Duodenal Ulcer Treatment Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape

Chapter 4. Duodenal Ulcer Treatment Market: Treatments Estimates & Trend Analysis

  • 4.1. Global Duodenal Ulcer Treatment Market: Treatments Dashboard
  • 4.2. Global Duodenal Ulcer Treatment Market: Treatments Movement Analysis
  • 4.3. Global Duodenal Ulcer Treatment Market by Treatments, Revenue
  • 4.4. Proton Pump Inhibitors
    • 4.4.1. Proton pump inhibitors market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. H2 Antagonists
    • 4.5.1. H2 Antagonists market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Antibiotics
    • 4.6.1. Antibiotics market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Other
    • 4.7.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Duodenal Ulcer Treatment Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Duodenal Ulcer Treatment Market: Route of Administration Dashboard
  • 5.2. Global Duodenal Ulcer Treatment Market: Route of Administration Movement Analysis
  • 5.3. Global Duodenal Ulcer Treatment Market Estimates and Forecasts, By Route of Administration, Revenue (USD Million)
  • 5.4. Oral
    • 5.4.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Parenteral
    • 5.5.1. Parenteral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Duodenal Ulcer Treatment Market: Distribution Channel Estimates & Trend Analysis

  • 6.1. Global Duodenal Ulcer Treatment Market: Distribution Channel Dashboard
  • 6.2. Global Duodenal Ulcer Treatment Market: Distribution Channel Movement Analysis
  • 6.3. Global Duodenal Ulcer Treatment Market Estimates and Forecasts, By Distribution Channel, Revenue (USD Million)
  • 6.4. Retail Pharmacies
    • 6.4.1. Retail Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. Hospital Pharmacies
    • 6.5.1. Hospital Pharmacies market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Other
    • 6.6.1. Other market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Duodenal Ulcer Treatment Market: Regional Estimates & Trend Analysis by Treatments, Route of Administration, and Distribution Channel

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company/Competition Categorization
  • 8.2. Vendor Landscape
    • 8.2.1. List of key distributors and channel partners
    • 8.2.2. Key company market share analysis, 2023
    • 8.2.3. GSK plc.
      • 8.2.3.1. Company overview
      • 8.2.3.2. Financial performance
      • 8.2.3.3. Product benchmarking
      • 8.2.3.4. Strategic initiatives
    • 8.2.4. Pfizer
      • 8.2.4.1. Company overview
      • 8.2.4.2. Financial performance
      • 8.2.4.3. Product benchmarking
      • 8.2.4.4. Strategic initiatives
    • 8.2.5. Abbott
      • 8.2.5.1. Company overview
      • 8.2.5.2. Financial performance
      • 8.2.5.3. Product benchmarking
      • 8.2.5.4. Strategic initiatives
    • 8.2.6. Merck KGaA
      • 8.2.6.1. Company overview
      • 8.2.6.2. Financial performance
      • 8.2.6.3. Product benchmarking
      • 8.2.6.4. Strategic initiatives
    • 8.2.7. NIHON GENERIC Co., Ltd.
      • 8.2.7.1. Company overview
      • 8.2.7.2. Financial performance
      • 8.2.7.3. Product benchmarking
      • 8.2.7.4. Strategic initiatives
    • 8.2.8. Novartis AG
      • 8.2.8.1. Company overview
      • 8.2.8.2. Financial performance
      • 8.2.8.3. Product benchmarking
      • 8.2.8.4. Strategic initiatives
    • 8.2.9. Bristol-Myers Squibb Company
      • 8.2.9.1. Company overview
      • 8.2.9.2. Financial performance
      • 8.2.9.3. Product benchmarking
      • 8.2.9.4. Strategic initiatives
    • 8.2.10. AstraZeneca
      • 8.2.10.1. Company overview
      • 8.2.10.2. Financial performance
      • 8.2.10.3. Product benchmarking
      • 8.2.10.4. Strategic initiatives
    • 8.2.11. Takeda Pharmaceutical Company Limited
      • 8.2.11.1. Company overview
      • 8.2.11.2. Financial performance
      • 8.2.11.3. Product benchmarking
      • 8.2.11.4. Strategic initiatives
    • 8.2.12. Eisai Co., Ltd.
      • 8.2.12.1. Company overview
      • 8.2.12.2. Financial performance
      • 8.2.12.3. Product benchmarking
      • 8.2.12.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Duodenal ulcer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 3 North America Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 4 North America Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 5 North America Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 6 U.S. Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 7 U.S. Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 8 U.S. Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 9 Canada Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 10 Canada Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 11 Canada Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 12 Mexico Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 13 Mexico Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 14 Mexico Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 15 Europe Duodenal ulcer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 16 Europe Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 17 Europe Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 18 Europe Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 19 Germany Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 20 Germany Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 21 Germany Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 22 UK Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 23 UK Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 24 UK Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 25 France Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 26 France Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 27 France Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 28 Italy Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 29 Italy Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 30 Italy Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 31 Spain Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 32 Spain Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 33 Spain Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 34 Denmark Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 35 Denmark Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 36 Denmark Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 37 Sweden Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 38 Sweden Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 39 Sweden Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 40 Norway Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 41 Norway Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 42 Norway Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 43 Asia Pacific Duodenal ulcer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 44 Asia Pacific Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 45 Asia Pacific Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 46 Asia Pacific Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 47 China Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 48 China Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 49 China Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 50 Japan Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 51 Japan Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 52 Japan Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 53 India Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 54 India Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 55 India Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 56 South Korea Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 57 South Korea Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 58 South Korea Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 59 Australia Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 60 Australia Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 61 Australia Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 62 Thailand Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 63 Thailand Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 64 Thailand Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 65 Latin America Duodenal ulcer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 66 Latin America Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 67 Latin America Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 68 Latin America Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 69 Brazil Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 70 Brazil Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 71 Brazil Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 72 Argentina Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 73 Argentina Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 74 Argentina Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 75 MEA Duodenal ulcer treatment market, by region, 2018 - 2030 (USD Million)
  • Table 76 MEA Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 77 MEA Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 78 MEA Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 79 South Africa Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 80 South Africa Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 81 South Africa Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 82 Saudi Arabia Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 83 Saudi Arabia Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 84 Saudi Arabia Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 85 UAE Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 86 UAE Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 87 UAE Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)
  • Table 88 Kuwait Duodenal ulcer treatment market, by treatment, 2018 - 2030 (USD Million)
  • Table 89 Kuwait Duodenal ulcer treatment market, by route of administration, 2018 - 2030 (USD Million)
  • Table 90 Kuwait Duodenal ulcer treatment market, by distribution channel, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Data triangulation techniques
  • Fig. 3 Market research approaches
  • Fig. 4 QFD modeling for market share assessment
  • Fig. 5 Market formulation & validation
  • Fig. 6 Duodenal ulcer treatment market: market outlook
  • Fig. 7 Duodenal ulcer treatment competitive insights
  • Fig. 8 Parent market outlook
  • Fig. 9 Related/ancillary market outlook
  • Fig. 10 Duodenal ulcer treatment market driver impact
  • Fig. 11 Duodenal ulcer treatment market restraint impact
  • Fig. 12 Duodenal ulcer treatment market: Treatment movement analysis
  • Fig. 13 Duodenal ulcer treatment market: Treatment outlook and key takeaways
  • Fig. 14 Proton Pump Inhibitors market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 15 H2 Antagonists market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 16 Antibiotics market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 17 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 18 Duodenal ulcer treatment market: Route of Administration movement analysis
  • Fig. 19 Duodenal ulcer treatment market: Route of Administration outlook and key takeaways
  • Fig. 20 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 21 Parenteral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 22 Duodenal ulcer treatment market: Distribution Channel movement analysis
  • Fig. 23 Duodenal ulcer treatment market: Distribution Channel outlook and key takeaways
  • Fig. 24 Retail Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Hospital Pharmacies market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Other market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Global duodenal ulcer treatment market: Regional movement analysis
  • Fig. 28 Global duodenal ulcer treatment market: Regional outlook and key takeaways
  • Fig. 29 Global duodenal ulcer treatment market share and leading players
  • Fig. 30 North America, by country
  • Fig. 31 North America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 32 U.S. key country dynamics
  • Fig. 33 U.S. market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 34 Canada key country dynamics
  • Fig. 35 Canada market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 36 Mexico key country dynamics
  • Fig. 37 Mexico market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 38 Europe market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 39 UK key country dynamics
  • Fig. 40 UK market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 41 Germany key country dynamics
  • Fig. 42 Germany market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 43 France key country dynamics
  • Fig. 44 France market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 45 Italy key country dynamics
  • Fig. 46 Italy market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 47 Spain key country dynamics
  • Fig. 48 Spain market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 49 Denmark key country dynamics
  • Fig. 50 Denmark market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Sweden key country dynamics
  • Fig. 52 Sweden market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 53 Norway key country dynamics
  • Fig. 54 Norway market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Asia Pacific market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 56 China key country dynamics
  • Fig. 57 China market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Japan key country dynamics
  • Fig. 59 Japan market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 60 India key country dynamics
  • Fig. 61 India market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 62 Thailand key country dynamics
  • Fig. 63 Thailand market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 South Korea key country dynamics
  • Fig. 65 South Korea market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 66 Australia key country dynamics
  • Fig. 67 Australia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 68 Latin America market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 69 Brazil key country dynamics
  • Fig. 70 Brazil market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 71 Argentina key country dynamics
  • Fig. 72 Argentina market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Middle East and Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 74 South Africa key country dynamics
  • Fig. 75 South Africa market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Saudi Arabia key country dynamics
  • Fig. 77 Saudi Arabia market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 78 UAE key country dynamics
  • Fig. 79 UAE market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 80 Kuwait key country dynamics
  • Fig. 81 Kuwait market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Market share of key market players- Duodenal ulcer treatment market